Human immunodeficiency virus type-1 (HIV-1) antigenic variation poses a great challenge for vaccine immunogen design to elicit broadly neutralizing antibodies (bNAbs). Over the last 10–15 years, great progress has been made to understand the conserved sites of sensitivity on HIV envelope glycoprotein spikes targeted by bNAbs. Plasma neutralization mapping and monoclonal antibody isolation efforts have revealed five major conserved epitope clusters. Most of this work has focused on subtype B and C-infected Caucasian or African donors. It is not clear if the same epitopes and epitope rank order preferences are also true in donors infected with different HIV-1 subtypes and with different racial backgrounds. To investigate this point, in this study we report the first attempt to profile the bNAb specificities of CRF01_AE-infected Malaysian plasmas. We first measured neutralization titers of 21 plasmas against a subtype A, B, and AE pseudovirus panel. This revealed that 14% (3 of 21) plasmas had cross-clade breadth. Focusing on the cross-neutralizing plasma P9, we used AE and JR-FL mutant pseudoviruses, gp120 monomer interference, and native polyacrylamide gel electrophoresis to better understand the neutralization specificity. P9 demonstrates CD4-binding-site specificity with trimer dependence and D368 independence.
Get full access to this article
View all access options for this article.
References
1.
HaynesBF, GilbertPB, McElrathMJ, et al.: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med, 2012; 366:1275–1286.
2.
KarasavvasN, BillingsE, RaoM, et al.: The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses, 2012; 28:1444–1457.
3.
Rerks-NgarmS, PitisuttithumP, NitayaphanS, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 2009; 361:2209–2220.
4.
SokD, BurtonDR: Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol, 2018; 19:1179–1188.
5.
ScanlanCN, PantophletR, WormaldMR, et al.: The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1—>2 mannose residues on the outer face of gp120. J Virol, 2002; 76:7306–7321.
6.
TrkolaA, PurtscherM, MusterT, et al.: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol, 1996; 70:1100–1108.
7.
WalkerLM, HuberM, DooresKJ, et al.: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature, 2011; 477:466–470.
8.
WalkerLM, PhogatSK, Chan-HuiPY, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science, 2009; 326:285–289.
9.
ZhouT, ZhengA, BaxaU, et al.: A neutralizing antibody recognizing primarily N-linked glycan targets the silent face of the HIV envelope. Immunity, 2018; 48:500.e506–513.e506.
10.
HemelaarJ, ElangovanR, YunJ, et al.: Global and regional molecular epidemiology of HIV-1, 1990–2015: A systematic review, global survey, and trend analysis. Lancet Infect Dis, 2019; 19:143–155.
11.
ChowWZ, BonAH, KeatingS, et al.: Extensive genetic diversity of HIV-1 in incident and prevalent infections among Malaysian blood donors: Multiple introductions of HIV-1 genotypes from highly prevalent countries. PLoS One, 2016; 11:e0161853.
12.
DoHT, NguyenDT, NguyenLAT, et al.: An alarmingly high proportion of HIV-1 isolates carrying mutations corresponding to resistance to antiretroviral drugs among HIV-positive high-risk groups in Central Vietnam: A substudy of the national sentinel survey. Jpn J Infect Dis, 2017; 70:621–627.
13.
MatsumotoC, ShinoharaN, SobataR, UchidaS, SatakeM, TadokoroK: Genetic analysis of HIV-1 in Japan: A comprehensive analysis of donated blood. Jpn J Infect Dis, 2017; 70:136–142.
14.
MenuE, TruongTX, LafonME, et al.: HIV type 1 Thai subtype E is predominant in South Vietnam. AIDS Res Hum Retroviruses, 1996; 12:629–633.
15.
MeratiTP, RyanCE, SpelmenT, et al.: CRF01_AE dominates the HIV-1 epidemic in Indonesia. Sex Health, 2012; 9:414–421.
16.
MotomuraK, KusagawaS, KatoK, et al.: Emergence of new forms of human immunodeficiency virus type 1 intersubtype recombinants in central Myanmar. AIDS Res Hum Retroviruses, 2000; 16:1831–1843.
17.
UedaS, WitaningrumAM, KhairunisaSQ, KotakiT, Nasronudin, KameokaM: Genetic diversity and drug resistance of HIV-1 circulating in North Sulawesi, Indonesia. AIDS Res Hum Retroviruses, 2019; 35:407–413.
18.
BinleyJM, LybargerEA, CrooksET, et al.: Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol, 2008; 82:11651–11668.
19.
GrayES, TaylorN, WycuffD, et al.: Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol, 2009; 83:8925–8937.
20.
MoorePL, GrayES, ShewardD, et al.: Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol, 2011; 85:3128–3141.
21.
SatherDN, StamatatosL: Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine, 2010; 28(Suppl. 2):B8–B12.
22.
TomarasGD, BinleyJM, GrayES, et al.: Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol, 2011; 85:11502–11519.
23.
WalkerLM, SimekMD, PriddyF, et al.: A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog, 2010; 6:e1001028.
24.
Doria-RoseNA, SchrammCA, GormanJ, et al.: Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 2014; 509:55–62.
25.
HraberP, KorberBT, LapedesAS, et al.: Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J Virol, 2014; 88:12623–12643.
26.
SokD, PauthnerM, BrineyB, et al.: A prominent site of antibody vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging glycans. Immunity, 2016; 45:31–45.
27.
BinleyJM, CayananCS, WileyC, SchulkeN, OlsonWC, BurtonDR: Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol, 2003; 77:5678–5684.
28.
LiM, GaoF, MascolaJR, et al.: Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol, 2005; 79:10108–10125.
29.
WuX, ParastAB, RichardsonBA, et al.: Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol, 2006; 80:835–844.
30.
MontefioriDC, KarnasutaC, HuangY, et al.: Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis, 2012; 206:431–441.
31.
BurtonDR, BarbasCF, 3rd, PerssonMA, KoenigS, ChanockRM, LernerRA: A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A, 1991; 88:10134–10137.
32.
WuX, YangZY, LiY, et al.: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science, 2010; 329:856–861.
33.
BuchacherA, PredlR, StrutzenbergerKet al.: Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization, AIDS Res Hum Retroviruses, 1994; 10:359–369.
34.
ThaliM, MooreJP, FurmanC, et al.: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol, 1993; 67:3978–3988.
35.
HuangJ, OfekG, LaubL, et al.: Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature, 2012; 491:406–412.
36.
LiaoHX, BonsignoriM, AlamSM, et al.: Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity, 2013; 38:176–186.
37.
CenterRJ, WheatleyAK, CampbellSM, et al.: Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine, 2009; 27:6605–6612.
38.
MorikawaY, OvertonHA, MooreJP, et al.: Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro. AIDS Res Hum Retroviruses, 1990; 6:765–773.
39.
ConnorRI, ChenBK, ChoeS, LandauNR: Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology, 1995; 206:935–944.
CrooksET, MoorePL, RichmanD, et al.: Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies, 2005; 14:101–113.
42.
BinleyJM, SandersRW, ClasB, et al.: A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol, 2000; 74:627–643.
43.
TongT, CrooksET, OsawaK, et al.: Multi-parameter exploration of HIV-1 virus-like particles as neutralizing antibody immunogens in guinea pigs, rabbits and macaques. Virology, 2014; 456–457:55–69.
44.
BinleyJM, KlassePJ, CaoY, et al.: Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol, 1997; 71:2799–2809.
45.
CrooksET, TongT, ChakrabartiB, et al.: Vaccine-elicited tier 2 HIV-1 neutralizing antibodies bind to quaternary epitopes involving glycan-deficient patches proximal to the CD4 binding site. PLoS Pathog, 2015; 11:e1004932.
46.
DitseZ, MuenchhoffM, AdlandE, et al.: HIV-1 subtype C-infected children with exceptional neutralization breadth exhibit polyclonal responses targeting known epitopes. J Virol, 2018; 92, DOI: 10.1128/JVI.00878-18.
47.
LandaisE, HuangX, Havenar-DaughtonC, et al.: Broadly neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort. PLoS Pathog, 2016; 12:e1005369.
48.
SatherDN, ArmannJ, ChingLK, et al.: Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol, 2009; 83:757–769.
49.
CrooksET, OsawaK, TongT, et al.: Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. Virology, 2017; 505:193–209.
50.
LaBrancheCC, HendersonR, HsuA, et al.: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. PLoS Pathog, 2019; 15:e1008026.
51.
LiY, ClevelandB, KlotsI, et al.: Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol, 2008; 82:638–651.
52.
TraversSA: Conservation, compensation, and evolution of N-linked glycans in the HIV-1 group M subtypes and circulating recombinant forms. ISRN AIDS, 2012; 2012:823605.
53.
BinleyJM, WrinT, KorberB, et al.: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol, 2004; 78:13232–13252.
54.
SokD, van GilsMJ, PauthnerM, et al.: Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A, 2014; 111:17624–17629.
55.
UtacheeP, JinnopatP, Isarangkura-Na-AyuthayaP, et al.: Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand. Microbes Infect, 2009; 11:334–343.
56.
DeshpandeS, PatilS, KumarR, et al.: HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms. Retrovirology, 2016; 13:60.
57.
Quinones-KochsMI, BuonocoreL, RoseJK: Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: Effects on protein function and the neutralizing antibody response. J Virol, 2002; 76:4199–4211.
LeeJH, AndrabiR, SuCY, et al.: A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic beta-hairpin structure. Immunity, 2017; 46:690–702.
60.
PantophletR, Ollmann SaphireE, PoignardP, ParrenPW, WilsonIA, BurtonDR: Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol, 2003; 77:642–658.
61.
WangW, NieJ, ProchnowC, et al.: A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology, 2013; 10:14.
62.
UtacheeP, NakamuraS, Isarangkura-Na-AyuthayaP, et al.: Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain. J Virol, 2010; 84:4311–4320.
63.
GeorgievIS, Doria-RoseNA, ZhouT, et al.: Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science, 2013; 340:751–756.
64.
Doria-RoseNA, Altae-TranHR, RoarkRS, et al.: Mapping polyclonal HIV-1 antibody responses via next-generation neutralization fingerprinting. PLoS Pathog, 2017; 13:e1006148.
65.
HuangJ, KangBH, IshidaE, et al.: Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity, 2016; 45:1108–1121.
66.
KrebsSJ, KwonYD, SchrammCA, et al.: Longitudinal analysis reveals early development of three MPER-directed neutralizing antibody lineages from an HIV-1-infected individual. Immunity, 2019; 50:677.e613–691.e613.
67.
D'AmelioR, BiselliR, NisiniR, et al.: Spectrotype of anti-gp120 antibodies remains stable during the course of HIV disease. J Acquir Immune Defic Syndr (1988), 1992; 5:930–935.
68.
JuB, LiD, RenL, et al.: Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor. Emerg Microbes Infect, 2018; 7:174.
69.
TongT, OsawaK, RobinsonJE, CrooksET, BinleyJM: Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120. J Virol, 2013; 87:9233–9249.
70.
Doria-RoseNA, KleinRM, ManionMM, et al.: Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol, 2009; 83:188–199.
71.
GrayES, MadigaMC, HermanusT, et al.: The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol, 2011; 85:4828–4840.
72.
HraberP, SeamanMS, BailerRT, MascolaJR, MontefioriDC, KorberBT: Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS, 2014; 28:163–169.
73.
SimekMD, RidaW, PriddyFH, et al.: Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol, 2009; 83:7337–7348.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
